For research use only. Not for therapeutic Use.
Omigapil maleate is a drug that was developed by Novartis and tested in clinical trials for its ability to help treat Parkinson/’s disease (PD) and amyotrophic lateral sclerosis (ALS). The development for PD and ALS have been terminated due to lack of benefit, but Santhera Pharmaceuticals bought the compound for development for the treatment of congenital muscular dystrophy (CMD).
| Catalog Number | R028763 |
| CAS Number | 200189-97-5 |
| Synonyms | CGP 3466B Maleate; (2Z)-N-Methyl-N-2-propyn-1-yldibenz[b,f]oxepin-10-methanamine 2-Butenedioate; N-Methyl-N-2-propynyldibenz[b,f]oxepin-10-methanamine (2Z)-2-Butenedioate; N-Methyl-N-2-propynyldibenz[b,f]oxepin-10-methanamine (Z)-2-Butenedioate; CGP |
| Molecular Formula | C23H21NO5 |
| Purity | ≥95% |
| Target | Apoptosis |
| Solubility | Soluble in DMSO > 10 mM |
| Storage | Store at +4C |
| IUPAC Name | N-(benzo[b][1]benzoxepin-5-ylmethyl)-N-methylprop-2-yn-1-amine;(Z)-but-2-enedioic acid |
| InChI | InChI=1S/C19H17NO.C4H4O4/c1-3-12-20(2)14-16-13-15-8-4-6-10-18(15)21-19-11-7-5-9-17(16)19;5-3(6)1-2-4(7)8/h1,4-11,13H,12,14H2,2H3;1-2H,(H,5,6)(H,7,8)/b;2-1- |
| InChIKey | SQAZQLMBEHYFJA-BTJKTKAUSA-N |
| SMILES | CN(CC#C)CC1=CC2=CC=CC=C2OC3=CC=CC=C31.C(=CC(=O)O)C(=O)O |
| Reference | </br>1: Yu Q, Sali A, Van der Meulen J, Creeden BK, Gordish-Dressman H, Rutkowski A, Rayavarapu S, Uaesoontrachoon K, Huynh T, Nagaraju K, Spurney CF. Omigapil treatment decreases fibrosis and improves respiratory rate in dy(2J) mouse model of congenital muscular dystrophy. PLoS One. 2013 Jun 6;8(6):e65468. doi: 10.1371/journal.pone.0065468. Print 2013. PubMed PMID: 23762378; PubMed Central PMCID: PMC3675144.</br> 2: Erb M, Meinen S, Barzaghi P, Sumanovski LT, Courdier-Früh I, Rüegg MA, Meier T. Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-alpha2 deficiency. J Pharmacol Exp Ther. 2009 Dec;331(3):787-95. doi: 10.1124/jpet.109.160754. Epub 2009 Sep 16. PubMed PMID: 19759319.</br></br> |
